Liver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES | Zendy

Adeel A. Butt | Zendy; Yan Peng | Zendy; Samia Aslam | Zendy; AbdulBadi AbouSamra | Zendy; Kenneth E. Sherman | Zendy; Obaid S. Shaikh | Zendy

Open Access

Liver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES

Author(s) -

Adeel A. Butt,

Yan Peng,

Samia Aslam,

AbdulBadi AbouSamra,

Kenneth E. Sherman,

Obaid S. Shaikh

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1097

Subject(s) - medicine , cirrhosis , confidence interval , hepatitis c virus , gastroenterology , incidence (geometry) , hepatitis b virus , hepatitis c , fibrosis , chronic hepatitis , hepatitis b , immunology , virus , physics , optics

For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research